• Process owner, Formulation lead and Workstream lead for BlueRock's Parkinson's program (DA02 program) as well as previous microglia-based cell therapy product- BRT-MG01 (for Lysosomal Storage Diseases) o Development of cell delivery solutions for delivery of iPSC derived dopaminergic neuronal cells o Development of cryopreservation formulations for improved cryopreservation efficiency, recovery and yield o Cross-functional coordination with different teams from cell cryopreservation stage till final cell suspension for injection (CSI) stage o Writing and reviewing program strategy documents, risk assessment documents for regulatory submission• Supporting development of BlueRock's other cell therapy products including Bemdaneprocel (BRT-DA01 for Parkinson’s disease) and OpCT-001 (for Inherent Retinal Diseases)

Projects-• Involved in all aspects of new product development including feasibility, process development, formulation optimization, scale-up, technology transfer & regulatory submissions• Development of new improved protein formulations with higher sensitivity & specificity for rapid clinical diagnosis of infectious diseases including HIV, Syphilis, Hepatitis C and COVID-19• Process improvement for protein formulations for high throughput & cost-effective manufacturing• Formulation optimization of protein formulations to improve their stability & shelf life• Stability studies of the optimized protein formulations as per ICH & FDA guidelines• Validation and optimization of process parameters for new manufacturing equipments/ processes• Scale up: Translation of new formulations from lab-scale to large-scale manufacturing • Investigational studies for occurrence of false positive results and other non-conformity issues

Research Projects-I. Pollen grains-based formulation development for oral delivery of proteins • To achieve successful oral delivery of proteins in the intestine while protecting protein molecules from the acidic pH & enzymes of gastric fluid.• Development of protein stabilization strategies, screening of excipients, optimization of protein & polymer concentrations, purification and characterization of pollen grains, characterization of pollen grain formulation, protein loading and release studies, protein conformational stability studies, statistical analysis• Published findings in International Journal of Pharmaceuticals II. Development of universal Influenza vaccine formulation• Development of smart polymeric bioconjugate (PLGA nanoparticles with M2e peptide (A conserved region of extracellular domain of Influenza A virus matrix protein 2)) with reversible and irreversible chemical linkage • Screening of various bioconjugation linkers/ techniques, polymer synthesis and characterization, characterization of bioconjugates, nanoparticle preparation and optimization, gold nanoparticle preparation and bioconjugation, protein loading and release studies, animal immunization studies, plasma antibody titer determination using ELISA, in vivo vaccine efficacy against Influenza virus (H1N1/09), statistical analysisIII. Electrospinning of elastin-like polypeptides (ELPs) for tissue engineering applications• Development of In-house electrospinning apparatus, process development & optimization, characterization of electrospun nanofibers, approaches for crosslinking of nanofibers IV. Processing of Timothy pollens as a suitable vehicle for oral drug/ protein delivery• Development of purification process for Timothy pollens, optimization of treatment steps, characterization of purified pollens